Anti-αvβ6 antibodies and uses thereof
US7943742B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2006 |
| Grant date | May 17, 2011 |
| Priority date | — |
| Expiry date | Aug 3, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αvβ6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin αvβ6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αvβ6.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.